Skip to main navigation
Skip to search
Skip to main content
Prinses Máxima Centrum Home
Nederlands
English
Search content at Prinses Máxima Centrum
Home
Profiles
Research Groups
Equipment
Research output
Prizes
Activities
Press/Media
Trial watch: Radioimmunotherapy for oncological indications
Norma Bloy
, Jonathan Pol
, Gwenola Manic
, Ilio Vitale
,
Alexander Eggermont
, Jérôme Galon
, Eric Tartour
, Laurence Zitvogel
, Guido Kroemer
, Lorenzo Galluzzi
Research output
:
Contribution to journal
›
Review article
›
peer-review
51
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Trial watch: Radioimmunotherapy for oncological indications'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Abscopal Effect
50%
Anticancer Immune Response
50%
Antineoplastic Agents
100%
Apoptosis
50%
Cancer Cells
50%
Cancer Patients
50%
Cell-extrinsic
50%
Chemotherapy
50%
Clinical Trials
50%
Damage-associated Molecular Patterns
50%
Extrinsic Mechanism
50%
Immunogenic Cell Death
50%
Immunostimulatory
50%
Immunotherapeutics
50%
In Cancer
50%
Oncologic
100%
Out-of-field
50%
Proliferative Arrest
50%
Radiation Effects
50%
Radiation Therapy
100%
Radioimmunotherapy
100%
Radiotherapy
50%
Recent Advances
50%
Transformed Cells
50%
Treatment Modalities
50%
Tumor-specific Immune Response
50%
Medicine and Dentistry
Abscopal Effect
33%
Anticarcinogen
66%
Cancer Cell
33%
Chemotherapy
33%
Clinical Trial
33%
Immune Response
66%
Immunogenic Cell Death
33%
Immunomodulating Agent
33%
Malignant Neoplasm
33%
Programmed Cell Death
33%
Radiation Therapy
100%
Radioimmunotherapy
100%
Specific Tumor
33%
Transformed Cell
33%
Immunology and Microbiology
Cancer Cell
50%
Cell Death
50%
Immune Response
100%
Immunomodulating Drugs
50%
Transformed Cell
50%
Neuroscience
Anticarcinogen
66%
Cell Death
33%
Immunomodulating Drugs
33%
Radiation Therapy
100%